Business
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026 IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"image","alt":"Eledon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Eledon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fe3DFQlar3TdaQ4TB5I5xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9","width":300,"height":76},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fe3DFQlar3TdaQ4TB5I5xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9","width":300,"height":76}},"lazy":false},{"type":"text","content":"100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study ","length":158,"tagName":"p"},{"type":"text","content":"FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation","length":117,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026","length":93,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights.","length":214,"tagName":"p"},{"type":"text","content":"“In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including important data updates in kidney and islet cell transplantation and FDA Orphan Drug designation for tegoprubart in liver transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “Looking ahead, we expect multiple catalysts in 2026, including regulatory engagements supporting the advancement of tegoprubart into Phase 3 development in kidney transplantation and discussions regarding a potential path to market in islet cell transplantation. We also plan to initiate several new clinical trials, including an investigator sponsored study in liver transplantation, and share new kidney transplant data from our Phase 2 BESTOW long-term extension ...